Park Medi World Share Price Gains Over 36% In 6 Months; More Potential Upside Ahead?

Through streamlined infrastructure and a full-time physician model, Park Medi World Ltd. (PMWL) runs an asset-owned, capital-efficient hospital network that focuses on providing inexpensive healthcare, mostly to middle-class and lower-class customers.

Park Medi World Ltd (PARKHOSPS) is now trading on the NSE at Rs 202.08 as of March 25, 2026. The stock has risen over 38.80% over the last year and 36.59% in the last six months, but it is now down 1.60% from its last close of Rs 205.36.

On a year-to-date basis, the stock has gained 34.81% in 2026. The brokerage company Ventura Securities has set a target price of Rs 284 in 24 months, which means a 40.6% rise from the current market price of Rs 202 as of March 25. This indicates that the stock has further upside.

"We initiate coverage with a BUY for a DCF-based price target of INR 284 (28.2x FY28 P/E), representing an upside of 38.4% from the current CMP of INR 205 over the next 24 months. Risks: Slower than expected occupancy ramp-up in newly commissioned hospitals Pecking Order: PMWL, Narayan Hrudalaya, Fortis Healthcare," said Ventura Securities in a report dated 24th March.

Dr. Ajit Gupta launched PMWL, a chain of multispecialty hospitals with a concentration on North India that offers a wide range of patients high-quality, reasonably priced treatment. As of December 31st, the company managed 14 NABH-accredited hospitals in important markets including Haryana, Delhi, Punjab, and Rajasthan with a total capacity of 3,250 beds, including 870 ICU beds and 67 operating rooms. As part of its capacity growth strategy, the corporation recently completed the commissioning of a 360-bed hospital in Agra in February, further solidifying its regional presence.

With the help of a fundamentally sound operating model, improved case mix, and controlled expansion, PMWL has shown significant operational progress in recent years. The firm reported Rs 1,394 Cr in sales for FY25, with EBITDA of Rs 373 Cr (26.8% margin) and PAT of Rs 205 Cr (14.7% margin). With 9MFY26 sales rising 17% YoY to Rs 1,219 Cr, growth momentum is still strong, and the company's asset-ownership model and operational efficiency are driving good profitability.

In the not-too-distant future, PMWL's revenue is expected to reach Rs 2,550 Cr at a compound annual growth rate (CAGR) of 22.3% during FY25-28E, as per the brokerage.
With a projected capital expenditure of Rs 383 Cr (with an average capital expenditure per bed of Rs 20.7 lakhs), the firm is anticipated to increase its bed capacity to 5,460 beds by FY28E with the addition of 1,850 beds. This growth will specifically take place in the underserved area of Uttar Pradesh. Long-term, with a strong emphasis on scalable expansion, management has laid out an ambitious plan to double its capacity to around 10,000 beds over the next seven years.

With outstanding return ratios of ROE of 19.2% and ROIC of 23.7% (FY25), PMWL has continuously shown industry-leading profitability, sustaining EBITDA margins of 25-27% and PAT margins of 15-17%. With an expected Rs 6.9-7.0 Tn in FY25 and a projected Rs 10.2-10.8 Tn by FY29, PMWL works in India's expanding healthcare delivery sector, indicating a 10-12% CAGR. Due to expanding healthcare demand, higher insurance coverage, and an increase in the frequency of lifestyle disorders, the industry is becoming more and more dominated by private companies, whose share is predicted to reach 69% by FY29, according to Ventura Securities.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.